Immuneering Corporation's stock is experiencing a notable increase following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The company reported that the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel achieved an overall response rate of 43%, significantly surpassing the 23% benchmark from the Phase 3 MPACT study. Additionally, the disease control rate reached 86%, compared to 48% in the MPACT study. These results have generated optimism about the potential of IMM-1-104, with plans for future pivotal clinical trials.
The trial also revealed positive outcomes from the combination of IMM-1-104 with modified FOLFIRINOX, where all evaluable patients experienced tumor shrinkage, including one patient with a complete reduction. The treatment's differentiated tolerability profile and its Fast Track designation from the FDA for various cancer indications have further bolstered investor confidence. Immuneering's plans to expand its clinical trials in 2025, including new Phase 2a combination arms and trials in melanoma and non-small cell lung cancer, have also contributed to the positive sentiment.
Immuneering Corporation's stock is currently priced at $1.97, a slight increase from the previous close of $1.96. Despite being early in the trading day, the volume is relatively low at 91,975 shares, representing just 4.60% of the average daily volume of 1,998,347 shares.